Released: September 19, 2016

Pharmacotherapies for Alcohol and Substance Abuse (PASA) Consortium
Congressionally Directed Medical Research Program
Alcohol and Substance Abuse Disorders Research Program
Upcoming Clinical Trial Research Funding Opportunity

The goal of the PASA Consortium is to fund study applications for developing new medications that can be brought to therapeutic use to improve treatment outcomes for alcohol and substance use disorders (ASUD), especially as related to post-traumatic stress disorder (PTSD) and traumatic brain injury (TBI). The upcoming Clinical Trial Research Funding Opportunity is focused on developing new medications that 1) already have an IND for human studies and 2) that can improve treatment outcomes for ASUD related to PTSD and TBI. The PASA Consortium is administered by a Management Core led by RTI International in collaboration with the Baylor College of Medicine and the Uniformed Services University.

The Management Core is responsible for planning, prioritizing, and soliciting proposals, and providing oversight and coordination for future proof-of-principle basic research studies and proof-of-principle human clinical trials supported by the Consortium. The Management Core will provide the administrative, protocol development and review, regulatory, statistical, resource, and data management/storage functions necessary to facilitate rapid development of research that would perhaps not otherwise be feasible without the Consortium approach. The Management Core contains multidisciplinary expertise and experience in support of ASUD research. The Management Core will manage the regulatory strategy for FDA compliance, in collaboration with the industry sponsor, leading to potential product development and licensing.

The PASA Consortium is providing the information in this pre-announcement to allow investigators time to plan and develop applications. The Request for Applications (RFA) is anticipated to be made public on or around December 1st, 2016. Pre-application and application deadlines will be available when the RFA is released. This pre-announcement should not be construed as an obligation by the PASA Consortium.  Additional information about PASA is available on their website:

Award Mechanism Eligibility Key Mechanism Elements Funding
  • Investigators at all academic levels (or equivalent)
  • Preproposal is required; application submission is by invitation only.

  • Test potential medications or medication combinations in PHASE II SAFETY AND PRELIMINARY EFFICACY TRIALS

  • Multiple site studies are encouraged in order to rapidly recruit target populations and potentially explore functional genetic polymorphisms for matching patients to medications.
  • Maximum funding of $3 million for total costs

  • Maximum period of performance is 24-30 months

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the website. The application package containing the required forms for each award mechanism will also be found on A listing of all CDMRP funding opportunities can be obtained on the website by performing a basic search using CFDA Number 12.420.

Applications must be submitted through the federal government's single-entry portal, Submission deadlines are not available until the Program Announcements are released. For email notification when Program Announcements are released go to the CDMRP website ( and select Subscribe to Funding Opportunities & Program Communications. For more information about the BCRP or other CDMRP-administered programs, please visit the CDMRP website (

Point of Contact:

CDMRP Public Affairs

Last updated Thursday, May 26, 2022